Praxis Precision Medicines (PRAX) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 387.9% versus a loss of 10.0%. Over five years, RYTM leads with a +702.7% price change compared with -13.4% for PRAX. Praxis Precision Medicines is the larger company by market cap ($7.26 billion vs $6.25 billion), about 1.2 times the size, while Rhythm Pharmaceuticals is growing revenue faster (+45.8% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRAX | RYTM |
|---|---|---|
| Share price | $259.86 | $90.78 |
| Market cap | $7.26B | $6.25B |
| 1-day change | -1.40% | +1.27% |
| YTD return | -11.83% | -15.19% |
| 1-year return | +387.91% | -9.96% |
| 5-year return | -13.42% | +702.65% |
| EPS (TTM) | $-12.95 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $189.76M |
| Revenue growth (YoY) | -100.00% | +45.83% |
| Net income (latest FY) | $-303.27M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | — | -101.19% |
| Net margin | — | -103.57% |
| 52-week high | $392.70 | $122.20 |
| 52-week low | $50.56 | $74.50 |
| Distance from 52-week high | -33.83% | -25.71% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +147.99% | +52.67% |
| Average volume | 410.73K | 669.81K |
| Shares outstanding | 27.92M | 68.85M |
| Employees | 168 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed RYTM by 397.9 percentage points over the past year.
- Rhythm Pharmaceuticals grew revenue faster in its latest fiscal year (+45.83% vs -100.00%).
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
PRAX vs RYTM FAQ
Which is bigger, Praxis Precision Medicines or Rhythm Pharmaceuticals?
Praxis Precision Medicines (PRAX) is larger, with a market capitalization of $7.26B compared with $6.25B for Rhythm Pharmaceuticals (RYTM).
Which stock has performed better over the past year, PRAX or RYTM?
PRAX returned +387.91% over the past 12 months, compared with -9.96% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are Praxis Precision Medicines and Rhythm Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.